quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:30:00·34d
PRRelease
Caris Life Sciences Inc. logo

Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients

CAI· Caris Life Sciences Inc.
Health Care
Original source

Companies

  • CAI
    Caris Life Sciences Inc.
    Health Care

Recent analyst ratings

  • Apr 13UpdateJefferies$28.00
  • Apr 10UpdatePiper Sandler$21.00
  • Apr 1UpdateGoldman$27.00
  • Feb 17UpdateRobert W. Baird$26.00
  • Dec 2UpdateCanaccord Genuity$28.00
  • Jul 14UpdateBofA Securities$31.00

Related

  • SEC23h
    SEC Form DEFA14A filed by Caris Life Sciences Inc.
  • SEC23h
    SEC Form DEF 14A filed by Caris Life Sciences Inc.
  • PR3d
    Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026
  • PR6d
    Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center
  • PR8d
    Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients
  • ANALYST10d
    Jefferies initiated coverage on Caris Life Sciences with a new price target
  • ANALYST13d
    Piper Sandler initiated coverage on Caris Life Sciences with a new price target
  • PR15d
    Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022